Bristol Myers Squibb: Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy (xanomeline and trospium chloride)

AI Briefing

• – Bristol Myers Squibb announces positive results from a Phase 4 study on its treatment transition from oral atypical antipsychotics to Cobenfy, with high treatment completion and no discontinuations due to lack of efficacy observed across different switch strategies.